Mesoblast stock
Price history
−26.30% over the period1 year: from $2.30 (November 20, 2025) to $1.70 (November 20, 2026), −26.30%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | $1.70 |
| October 30, 2026 | $2.26 |
| September 30, 2026 | $2.11 |
| August 31, 2026 | $2.36 |
| July 31, 2026 | $2.05 |
| June 30, 2026 | $1.96 |
| May 29, 2026 | $2.14 |
| April 30, 2026 | $2.12 |
| March 31, 2026 | $2.16 |
| February 27, 2026 | $2.24 |
| January 30, 2026 | $2.53 |
| December 31, 2025 | $2.72 |
| November 28, 2025 | $2.71 |
| November 20, 2025 | $2.30 |
At a glance
The company
Develops regenerative medicine products based on mesenchymal lineage cells, such as Ryoncil, for inflammatory and heart diseases
Latest results
Quarter to June 30, 2026 · EPS -$0.01 (estimate $0.00)
TickerLandia's take on Mesoblast
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−48.79% from the 52-week high
Analysts · 5 analysts
Average target$3.51+106.88% vs. price
Buy 5 · Hold 0 · Sell 0
TickerLandia Fingerprint: Mesoblast
Compared with similar companies: very low earnings stability.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.
Pricehigh61
How much it costs relative to what it produces.
Metric Value Position in group Forward P/E 82.4 90 Price/book 2.74 20 Price/sales 18.4 75 Profitabilitylow28
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 80.0% 60 Operating margin −42.6% 19 ROE −9.9% 22 ROA −4.1% 27 Net margin −47.8% 14 Earnings stabilityvery low18
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 403.9% 25 Loss-making yearscounts in reverse: lower means more earnings stability 5 of 5 annual reports 11 Growthhigh71
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) −68.62% 26 Revenue growth (year over year) +390.70% 96 Average revenue growth (3 years) +152.15% 92 Financial strengthlow32
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Current ratio 2.44 29 Interest coverage −2.58 25 Debt/equitycounts in reverse: lower means more financial strength 0.22 41 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumweak21
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −28.61% 10 Relative strength (6 months) −15.78% 27 1-year return −26.30% 15 Distance from 200-day average −20.73% 30 Riskhigh76
How much the price swings.
Metric Value Position in group Volatility (60 days) 65.2% 83 Beta (1 year) 1.40 79 Maximum drawdown (12 months) 44.8% 67
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Mesoblast is pricier than similar companies
Mesoblast's Forward P/E: 82.4, +128% against the median of a group of 9 similar companies (36.1).
Compared with 9 similar companies
| Metric | Mesoblast | Position in the group | Band |
|---|---|---|---|
| Forward P/E | 82.4 | High | |
| Operating margin | -42.6% | Low | |
| ROE | -9.9% | Low | |
| Debt/equity | 0.22 | Middle | |
| Price/book | 2.74 | Middle |
Grey band: the middle half of the group; tick: the median; dot: Mesoblast. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$68.91M
Latest quarter · Q2 2026
Net income
-$17.34M
Latest quarter · Q2 2026
Quarterly net margin
-25.2%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $2.21B
- EPS
- -$0.07
- Volume
- 4.88M
- Daily trading
- €4.23M
- Dividend yield
- 0.00%
How Mesoblast is changing
All resultsRevenue grew 74.5% a year on average over the last 5 years
Operating margin rose from −923.7% to −42.6%
Shares outstanding up 114.0% in 5 years
Returns
Mesoblast returns
$1,000 invested in Mesoblast 5 years ago, on November 22, 2021, would be worth $1,064 today: +6.41% in total, +1.25% per year. This is the price return only: dividends are excluded.
| Period | Mesoblast | S&P/ASX 200 | $1,000 becomes |
|---|---|---|---|
| 1 month | −3.69% | −2.54% | $963 |
| 6 months | −14.82% | +1.13% | $852 |
| Year to date | −37.68% | −1.40% | $623 |
| 1 year | −26.30% | +0.47% | $737 |
| 3 years | +389.78% | +21.74% | $4,898 |
| 5 years | +6.41% | +16.86% | $1,064 |
| 10 years | +48.63% | +60.57% | $1,486 |
Over the last 6 months it has done better than 10% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Mesoblast: technical analysis
Mesoblast is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 81.9% below its all-time closing high ($9.38, October 24, 2011).
- Trend
- Downward
- RSI (14 sessions)
- 34
- Between 30 and 70
- vs 200-session average
- −20.73%
Active signals
New 52-week low.
since November 19, 2026
Support and resistance
Price areas where Mesoblast has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$2.08+22.42%2 touches, last on October 12, 2026
- Resistance$2.00+18.09%3 touches, last on September 16, 2026
- Resistance$1.93+13.89%6 touches, last on July 10, 2026
- Last price$1.70
- No support below: the price is near the lows of the year
Volatility and risk
Over the last year it has moved more than the S&P/ASX 200.
- Beta (1 year) vs S&P/ASX 200
- 1.40
- Volatility (60 sessions, annualised)
- 65.2%
- Largest fall in the last year
- −44.79%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Mesoblast: seasonality
Average monthly price change over 22 years
Over the last 22 years, the strongest month for Mesoblast has been July: +9.03% on average, positive in 16 years out of 22. The weakest has been June: −5.99% on average, positive in 6 years out of 22. November, the current month, has been positive in 13 years out of 21 (+5.22% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +3.26% | +1.49% | 13 of 22 |
| February | +2.22% | +2.09% | 13 of 22 |
| March | +4.09% | −0.10% | 11 of 22 |
| April | +8.29% | −4.11% | 7 of 22 |
| May | +0.50% | +0.60% | 12 of 22 |
| June | −5.99% | −4.26% | 6 of 22 |
| July | +9.03% | +4.26% | 16 of 22 |
| August | −3.38% | −5.91% | 9 of 22 |
| September | +5.25% | +0.14% | 11 of 22 |
| October | +0.47% | +0.10% | 11 of 22 |
| November | +5.22% | +3.99% | 13 of 21 |
| December | +2.35% | +1.03% | 12 of 21 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Mesoblast and its competitors
Melbourne-based Mesoblast has existed since 2004 and works on regenerative medicine products in Australia. Its platform relies on mesenchymal lineage cells, and the portfolio includes Ryoncil, aimed at graft versus host disease in children and at inflammatory bowel conditions, Revascor for hypoplastic left heart syndrome, and remestemcel-L, which is in Phase III trials for heart failure and degenerative back pain. The pipeline also includes MPC-300-IV for rheumatoid arthritis and MPC-25-IC for acute myocardial infarction.
- Headquarters
- Melbourne, Australia
- Employees
- 108
- Founded
- 2004
- Chief executive
- Silviu Itescu
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| MesoblastMSB | $1.48B | -42.6% | — | −14.82% |
| Neuren PharmaceuticalsNEU | $1.83B | 19.9% | 144.0 | +68.84% |
| Metis TechBio7666 | $1.11B | -131.2% | — | −63.08% |
| InSilico Medicine Cayman TopCo3696 | $2.59B | -6.9% | — | −36.46% |
| Telix PharmaceuticalsTLX | $2.92B | 6.2% | 92.3 | −7.71% |
| 3SBio1530 | $4.56B | 60.3% | 3.90 | −34.08% |
Same industry or related industries, similar size. Compare Mesoblast with its competitors · Full profile
